|
gptkb:D07451
|
gptkb:DrugBank
|
|
gptkb:D01977
|
Hyperandrogenism
|
|
gptkb:R-HSA-264876.7
|
Reactome pathway
|
|
gptkb:R-HSA-264876.8
|
CREB phosphorylation through the activation of CaMKII
|
|
gptkb:R-HSA-264876.2
|
Reactome pathway
|
|
gptkb:D06013
|
gptkb:DrugBank
|
|
gptkb:D00544
|
gptkb:DrugBank
|
|
gptkb:R-HSA-1237044
|
Reactome pathway
|
|
gptkb:D006701
|
Histocompatibility Antigens, Class I
|
|
gptkb:C6833
|
Clinical trial
|
|
gptkb:R-HSA-264876.5
|
CREB phosphorylation through the activation of CaMKII
|
|
gptkb:P33261
|
gptkb:GLUT4
|
|
gptkb:D00744
|
Meclizine
|
|
gptkb:P21912
|
gptkb:Dopamine_receptor_D2_protein_in_Homo_sapiens
|
|
gptkb:Crossref_Funder_ID:_501100011878
|
gptkb:National_Natural_Science_Foundation_of_China
|
|
gptkb:R-HSA-264876.4
|
Reactome pathway
|
|
gptkb:D011470
|
Psoriasis
|